label: (223)RaCl2
label_lc: (223)racl2
description: "A radium molecular entity with formula (223)RaCl2. Used as as a radiotherapeutic agent for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. An alpha-emitter, radium-223 has a half-life of 11.4 days."